سعر لانثاريكس 500مجم 30 قرص مضغ 2022

Lantharex lanthanum carbonate 500 mg chewable tablets, pack of 30 (Saja / Andalous Pharma, Egypt); phosphate binder for hyperphosphataemia.

• Phosphate binder to reduce serum phosphate in patients with end-stage renal disease (ESRD).Population: Adults with ESRDDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions are gastrointestinal (nausea, vomiting, abdominal pain), generally abating over time.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to lanthanum carbonate or any ingredient of the formulation.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Bowel obstruction, including ileus and faecal impaction.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious gastrointestinal obstruction, ileus, subileus, perforation and faecal impaction have been reported, some requiring surgery; risk factors include abnormal GI anatomy, hypomotility disorders and concomitant drugs with these effects. Consider stopping if severe GI symptoms occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Radio-opaque: may give the appearance of an imaging agent on abdominal X-ray; product residue reported during endoscopy.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Compounds that bind cationic antacids (e.g. quinolones, ampicillin, tetracyclines, thyroid hormones, ACE inhibitors, statins, antimalarials)Do not give such compounds within 2 hours of lanthanum dosing.DailyMed (U.S. National Library of Medicine)
• Oral quinolone antibioticsCiprofloxacin bioavailability fell about 50%; give quinolones at least 1 hour before or 4 hours after lanthanum.DailyMed (U.S. National Library of Medicine)
• LevothyroxineLevothyroxine bioavailability fell about 40%; separate by at least 2 hours and monitor TSH.DailyMed (U.S. National Library of Medicine)

• Case-report data in pregnancy are insufficient to identify a drug-associated risk; no adverse developmental effects in rats/rabbits at 3 and 2.5 times the MRHD, while 5 times the MRHD in rabbits caused maternal toxicity, post-implantation loss and reduced fetal weight.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; the US label advises using a non-lanthanum phosphate binder in lactating women.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Lanthanum carbonate: Forms insoluble lanthanum phosphate complexes in the GI tract, reducing dietary phosphate absorption.